ALPMY News and Press, Astellas Pharma Inc. ADR From 12/17/23

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children PR Newswire - Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium - TOKYO , ...

2023-12-15 18:20:05 ET More on Merck, Pfizer, etc. Pfizer: Dividend Boost At The Right Time Pfizer 2024 Guidance - Relentless COVID Pain Isn't Over Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Merck gets FDA approval for kidney cancer drug Welireg ...

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer PR Newswire – PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – &...

2023-12-14 07:47:47 ET More on Apellis Pharma Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings C...

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics PR Newswire Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco, CA , along with ...

Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause PR Newswire First-in-class treatment option reduces number and intensity of hot flashes and night sweats TOKYO , Dec. 10, 2023...

2023-12-08 04:54:49 ET More on Pfizer, Astellas Pharma Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Astella...

2023-12-01 09:18:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earn...

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire – Results of pivotal confirmatory trial found...

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy PR Newswire Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant redu...